Cost-Utility and Cost-Effectiveness Analyses of Face-to-Face Versus Telephone-Based Nonpharmacologic Multidisciplinary Treatments for Patients With Generalized Osteoarthritis

被引:14
|
作者
Cuperus, Nienke [1 ]
van den Hout, Wilbert B. [2 ]
Hoogeboom, Thomas J. [3 ]
van den Hoogen, Frank H. J. [1 ]
Vlieland, Thea P. M. Vliet [2 ]
van den Ende, Cornelia H. M. [1 ]
机构
[1] Sint Maartensklin, Nijmegen, Netherlands
[2] Leiden Univ, Med Ctr, Leiden, Netherlands
[3] Maastricht Univ, NL-6200 MD Maastricht, Netherlands
关键词
KNEE OSTEOARTHRITIS; RHEUMATOID-ARTHRITIS; HEALTH; CARE; MANAGEMENT; HIP; RECOMMENDATIONS; TRIAL; RESPONSIVENESS; ECONOMICS;
D O I
10.1002/acr.22709
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To evaluate, from a societal perspective, the cost utility and cost effectiveness of a nonpharmacologic face-to-face treatment program compared with a telephone-based treatment program for patients with generalized osteoarthritis (GOA). Methods. An economic evaluation was carried out alongside a randomized clinical trial involving 147 patients with GOA. Program costs were estimated from time registrations. One-year medical and nonmedical costs were estimated using cost questionnaires. Quality-adjusted life years (QALYs) were estimated using the EuroQol (EQ) classification system, EQ rating scale, and the Short Form 6D (SF-6D). Daily function was measured using the Health Assessment Questionnaire (HAQ) disability index (DI). Cost and QALY/effect differences were analyzed using multilevel regression analysis and cost-effectiveness acceptability curves. Results. Medical costs of the face-to-face treatment and telephone-based treatment were estimated at (sic)387 and (sic)252, respectively. The difference in total societal costs was nonsignificantly in favor of the face-to-face program (difference (sic)708; 95% confidence interval [95% CI] -(sic)5,058, (sic)3,642). QALYs were similar for both groups according to the EQ, but were significantly in favor of the face-to-face group, according to the SF-6D (difference 0.022 [95% CI 0.000, 0.045]). Daily function was similar according to the HAQ DI. Since both societal costs and QALYs/effects were in favor of the face-to-face program, the economic assessment favored this program, regardless of society's willingness to pay. There was a 65-90% chance that the face-to-face program had better cost utility and a 60-70% chance of being cost effective. Conclusion. This economic evaluation from a societal perspective showed that a nonpharmacologic, face-to-face treatment program for patients with GOA was likely to be cost effective, relative to a telephone-based program.
引用
收藏
页码:502 / 510
页数:9
相关论文
共 44 条
  • [31] Evaluating the Cost-Effectiveness of Celecoxib versus Ibuprofen and Naproxen in Patients with Osteoarthritis in United Arab Emirates Based on the PRECISION Trial
    Chirikov, Viktor V.
    Walker, Chris
    Stephens, Jennifer M.
    Schepman, Patricia
    Chambers, Richard
    Bakir, Mahmoud
    Poorman, Gregory W.
    Haider, Seema
    Farghaly, Mohammed
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 409 - 420
  • [32] COST-EFFECTIVENESS AND COST-UTILITY OF HOME-BASED HYPNOTHERAPY USING COMPACT DISC VERSUS INDIVIDUAL HYPNOTHERAPY BY A THERAPIST FOR PEDIATRIC IRRITABLE BOWEL SYNDROME AND FUNCTIONAL ABDOMINAL PAIN (SYNDROME)
    van Barreveld, M.
    Rutten, J.
    Vlieger, A.
    Frankenhuis, C.
    George, E.
    Goreneweg, M.
    Norbruis, O.
    Tjon a Ten, W.
    van Wering, H.
    Merkus, M.
    Benninga, M.
    Dijkgraaf, M.
    VALUE IN HEALTH, 2015, 18 (07) : A628 - A628
  • [33] Cost-effectiveness analysis of telephone-based cognitive behaviour therapy compared to treatment as usual CBT for cancer patients: Evidence from a small, randomised controlled trial
    Rodrigues, Pedro
    Watson, Maggie
    White, Charlotte
    Lynch, Andrea
    Mohammed, Kabir
    Sagoo, Gurdeep S.
    PSYCHO-ONCOLOGY, 2021, 30 (10) : 1691 - 1698
  • [34] 10-year cost-effectiveness analyses of response-based fremanezumab use in migraine patients with inadequate response to prior preventive treatments
    Smolen, Lee
    Thompson, Stephen
    Klein, Timothy
    Cohen, Joshua M.
    Gandhi, Sanjay K.
    CEPHALALGIA, 2019, 39 (1_SUPPL) : 400 - 400
  • [35] COST-EFFECTIVENESS OF CELECOXIB VERSUS IBUPROFEN AND NAPROXEN IN PATIENTS WITH OSTEOARTHRITIS IN UNITED ARAB EMIRATES AND SAUDI ARABIA BASED ON RESULTS FROM THE PRECISION TRIAL
    Ahmed, O. H.
    Chirikov, V
    Walker, C.
    Stephens, J. M.
    Schepman, P.
    Chambers, R.
    Bakir, M.
    Poorman, G.
    Haider, S.
    VALUE IN HEALTH, 2020, 23 : S130 - S130
  • [36] Acceptability, effectiveness and cost-effectiveness of blended cognitive-behavioural therapy (bCBT) versus face-to-face CBT (ftfCBT) for anxiety disorders in specialised mental health care: A 15-week randomised controlled trial with 1-year follow-up
    Romijn, Geke
    Batelaan, Neeltje
    Koning, Jeroen
    van Balkom, Anton
    de Leeuw, Aart
    Benning, Friederike
    van Roijen, Leona Hakkaart
    Riper, Heleen
    PLOS ONE, 2021, 16 (11):
  • [37] Effectiveness and cost-effectiveness of face-to-face and electronic brief interventions versus screening alone to reduce alcohol consumption among high-risk adolescents presenting to emergency departments: three-arm pragmatic randomized trial (SIPS Junior high risk trial)
    Deluca, Paolo
    Coulton, Simon
    Alam, Mohammed Fasihul
    Boniface, Sadie
    Donoghue, Kim
    Gilvarry, Eilish
    Kaner, Eileen
    Lynch, Ellen
    Maconochie, Ian
    McArdle, Paul
    McGovern, Ruth
    Newbury-Birch, Dorothy
    Patton, Robert
    Pellat-Higgins, Tracy
    Phillips, Ceri
    Phillips, Thomas
    Pockett, Rhys D.
    Russell, Ian T.
    Strang, John
    Drummond, Colin
    ADDICTION, 2022, 117 (08) : 2200 - 2214
  • [38] The cost-effectiveness of acute stroke treatments: A comparison of using the subset of patients included in randomized trials versus a more population-based perspective
    Matchar, DB
    Samsa, GP
    STROKE, 2005, 36 (02) : 492 - 492
  • [39] Cost-effectiveness and cost-utility analyses of hospital-based home care compared to hospital-based care for children diagnosed with type 1 diabetes; a randomised controlled trial; results after two years’ follow-up
    Irén Tiberg
    Björn Lindgren
    Annelie Carlsson
    Inger Hallström
    BMC Pediatrics, 16
  • [40] Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland
    Braendle, M.
    Azoulay, M.
    Greiner, R.-A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2007, 45 (04) : 203 - 220